Abstract
Introduction Serum Natrium abnormalities are largely observed in older adults and are associated with higher risks. Less is known about the association between serum Natrium variations and medial temporal brain structures, mainly involved in cognition and memory. The study’s objective was to explore the association between serum Natrium and Hippocampus volume and to assess associated cognitive risks.
Methods Non-demented ADNI3 participants (healthy controls (HC) and with mild cognitive impairment (MCI)) with complete serum Natrium, ADAS13 score, and Hippocampus volume at baseline were included. Linear and non-linear associations were evaluated. To assess the odds of MCI, logistic regression adjusted was performed. Holm method was used to adjust for Family-wise error rate in the main analysis and reported as a q-value.
Results A total of 469 cases with a median age of 70 years (IQR: 66, 76) were included. The median serum Natrium level was 141 (IQR: 139, 142). Serum Natrium levels showed a significant association with Hippocampus volume in the total study population and MCI subgroup (Adj.ßMCI=-95 (−162, −28), p=0.006, q=0.036). Serum Natrium levels did not show a significant association neither with the ADAS13 total score (Adj.ßTotal=-0.04(−0.28, 0.21), p=0.8) nor with the odds of being diagnosed with MCI at baseline (ORMCI= 1.00(0.88, 1.13), p= 0.935).
Conclusions Normal Serum Natrium variations were significantly associated with Hippocampus volumes depending on the underlying neurodegenerative pathology, thus, without predicting clinically relevant cognitive adversity. Further studies are needed to better understand the mechanisms and assess protective factors.
Key findings
Serum Natrium levels within normal ranges were significantly associated with Hippocampus volume.
The association between Serum Natrium levels and Hippocampus volume was particularly significant in participants with mild cognitive impairment.
There was no significant association between serum Natrium and ADAS13 total score.
Serum Natrium levels within normal ranges did not predict concomitant risk of mild cognitive impairment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is funded by the National Institute on Aging (National Institutes of Health Grant U19 AG024904). ADNI is made possible with funding from the NIH and private sector support detailed at https://adni.loni.usc.edu/about/.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: https://adni.loni.usc.edu/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Declarations
Data availability
All data used in the manuscript is available at https://adni.loni.usc.edu.
Declaration of conflict of interest
the authors declare they have no conflict of interest.
Ethical approval and consent
ADNI was performed in accordance with the Declaration of Helsinki. Ethical approval was obtained from local IRBs corresponding to each ADNI’s recruitment center. All participants gave written consent. The current study is based on a secondary analysis of anonymized data and respecting ADNI’s data use agreement (DUA).
Declaration of funding
AH did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. Data collection and sharing for ADNI project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI; National Institutes of Health Grant U19 AG024904). ADNI is made possible with funding from the NIH and private sector support detailed at https://adni.loni.usc.edu/about/.
Author contributions
AH has full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the analysis, visualization, drafting, and editing of the manuscript.
